AbOliGo
Private Company
Funding information not available
Overview
AbOliGo is addressing a critical bottleneck in multiomic research by providing rapid, scalable, and high-quality antibody-oligonucleotide conjugates (AOCs). The company's proprietary conjugation technology platform allows for the conversion of virtually any antibody into a conjugate in just three days, overcoming the scarcity and slow production that has hindered multiplexed spatial and single-cell analysis. With a focus on technical innovation, automated manufacturing, and commercial expansion, AbOliGo aims to democratize access to AOCs, empowering researchers in fields like neuroscience and oncology. The company is led by an experienced team with backgrounds in reagent development, scaling life science businesses, and conjugation chemistry.
Technology Platform
Proprietary, rapid, and scalable conjugation methodology for producing antibody-oligonucleotide conjugates (AOCs) with miniaturized input, automated manufacturing, and stringent QC.
Opportunities
Risk Factors
Competitive Landscape
AbOliGo competes against slow, in-house academic conjugation labs, limited custom services from some platform companies (e.g., 10x Genomics), and a few niche reagent providers. Its primary differentiator is the combination of speed (3-day turnaround), scale (µg to mg), and a focus on rigorous QC and reproducibility for the research market.